Stock listing
Citius Oncology, Inc.
Selected listing: CTOR · NASDAQ · USD · US
Citius Oncology, Inc. (NASDAQ:CTOR), Health Technology. Latest release Aug 14, 2026: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results…
- Ticker
- NASDAQ:CTOR
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
About Citius Oncology, Inc.
Citius Oncology, Inc. is a public company traded under the ticker CTOR in the American market. Citius Oncology focuses on developing innovative therapies for cancer treatment.
Latest news from Citius Oncology, Inc.
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
August 12, 2026
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
August 5, 2026
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
July 21, 2026
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
June 1, 2026
Research Citius Oncology, Inc.
Citius Oncology, Inc. company profile
View the public company page for Citius Oncology, Inc. on 6ix.
Citius Oncology, Inc. news
Read company news and market updates connected to Citius Oncology, Inc..
Citius Oncology, Inc. investor events
Find investor webinars, events, and replay context for Citius Oncology, Inc..